Charles Robb
Equibles does not estimate personal net worth.
Get an email with a short summary when Corcept Therapeutics Inc publishes a filing, an earnings call transcript or a press release.
Get CORT alertsAbout Charles Robb
The proxy statement of Corcept Therapeutics Inc reports total compensation of $6,380,500 for Charles Robb in fiscal 2025, including a base salary of $711,413. Disclosed compensation is on record for 9 fiscal years. Corcept Therapeutics Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Corcept Therapeutics Inc includes Joseph K. Belanoff (CEO and Board Member), James N. Wilson (Chairman and Board Member), Atabak Mokari (CFO) and 7 others.
Affiliation history
-
Corcept Therapeutics Inc (CORT)
Proxy statement
CurrentStart not stated–present
Last confirmed April 17, 2026
-
Start not stated–2020-04-27
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Corcept Therapeutics Inc
- Joseph K. Belanoff CEO, Board Member
- James N. Wilson Chairman, Board Member
- Atabak Mokari CFO
- Joshua M. Murray CFO, Head of Investor Relations, Board Member
- Daniel N. Swisher COO
- J.D. Lyon Chief Accounting Officer
- Joseph D. Lyon Chief Accounting Officer
- Daniel N. Swisher, Jr. Board Member
- David L. Mahoney Board Member
- G. Leonard Baker, Jr. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $711,413 | $6,380,500 |
| 2024 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $686,273 | $4,138,371 |
| 2023 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $659,333 | $3,956,718 |
| 2022 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $627,500 | $3,203,809 |
| 2021 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and | $562,575 | $5,257,596 |
| 2020 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $474,380 | $2,914,438 |
| 2019 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary Amounts shown do not reflect compensation actually received by the named executive officers or the actual value that may be recognized by the named executive officers with respect to these awards in the future. Amounts reported constitute the grant date fair value of option awards as calculated under FASB ASC Topic 718. The relevant assumptions used to calculate the value of the option awards are set forth in Part IV – Item 15 – Financial Statements, Notes to Consolidated Financial Statements, Note 7 – “Preferred Stock and Stockholders’ Equity – Stock-Based Compensation Related to Employee and Director Options” in our Annual Report on Form 10-K for the year ended December 31, 2021. In February 2021, our Board approved a one-time payment of a $10,892 tax gross-up to reimburse Dr. Belanoff for an additional tax liability he incurred arising from a computational error made by the Company in connection with his net (cashless) exercise of stock options in 2019. Dr. Hunt’s base salary and bonus amounts are established in U.S. dollars as presented in the table and converted into pounds sterling on each payroll date using the exchange rate reported by Xe Currency Exchange as of the payment date. Effective March 1, 2021, Mr. Mokari was appointed as our Chief Financial Officer. Mr. Robb served as our Chief Financial Officer until February 28, 2021. Effective March 1, 2021, Mr. Robb was promoted to Chief Business Officer and Secretary. | $456,133 | $2,610,359 |
| 2018 | Corcept Therapeutics Inc (CORT) | Chief Business Officer and Secretary | $436,667 | $2,845,667 |
| 2017 | Corcept Therapeutics Inc (CORT) | Chief Financial Officer and Secretary | $397,929 | $1,780,518 |
Recent activity
No call appearances or filed executive changes recorded yet.